169 Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.

168 Purinergic receptors in the carotid body as a new drug target for controlling hypertension.

167 Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO).

166 Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA).

165 Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities.

164 Treatment of otitis media by transtympanic delivery of antibiotics.

163 A selective inhibitor of the kinetoplastid proteasome (GNF6702) is identified that is highly efficacious in vivo, clearing the parasites that cause leishmaniasis, Chagas disease and sleeping sickness from mice, highlighting the possibility of developing a single class of drugs for these neglected diseases.

162 Like citrate, the molecule hydroxycitrate is shown to inhibit growth of the crystal that is the principal component of kidney stones, suggesting that hydroxycitrate could be another treatment for kidney stone disease.

161 Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors.

160 Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels.

159 Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma.

158 Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.

157 On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system.

156 Precision multidimensional assay for high-throughput microRNA drug discovery.

155 Discovery of cahuitamycins as biofilm inhibitors derived from a convergent biosynthetic pathway.

154 Long-acting cocaine hydrolase for addiction therapy.

153 BRD4 is a novel therapeutic target for liver fibrosis.

152 Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis.

151 Structural studies give insight into how a human sodium channel involved in pain perception can be selectively inhibited.

150 Yeast-based screening identifies the benzodiazepine drug lorazepam as a non-selective positive allosteric modulator of the G-protein-coupled receptor (GPCR) GPR68; homology modelling and molecular docking of 3.1 million molecules found a new compound, ‘ogerin’, as a potent GPR68 modulator, which suppressed recall in fear conditioning in wild-type mice, and the general method of combining physical and structure-based screening may lead to the discovery of selective ligands for other GPCRs.

Free Images for Presentation: sunipix SUNIPIX